Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Rating of “Buy” from Brokerages

Compugen Ltd. (NASDAQ:CGEN) has been given a consensus recommendation of “Buy” by the five research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $5.00.

Several brokerages recently issued reports on CGEN. Weiss Ratings raised Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating on shares of Compugen in a research report on Tuesday. Leerink Partners decreased their price target on Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, May 21st. Finally, Wall Street Zen lowered Compugen from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CGEN. Platform Technology Partners boosted its stake in shares of Compugen by 10.0% in the 1st quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 5,000 shares during the last quarter. State Street Corp grew its holdings in Compugen by 3.9% during the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after acquiring an additional 14,701 shares during the period. Two Sigma Investments LP grew its holdings in Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 18,929 shares during the period. Glenmede Trust Co. NA raised its position in shares of Compugen by 187.5% in the 1st quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 22,500 shares in the last quarter. Finally, Bank Hapoalim BM bought a new position in shares of Compugen in the 4th quarter worth about $37,000. Institutional investors own 12.22% of the company’s stock.

Compugen Trading Up 4.8%

Shares of CGEN stock opened at $2.41 on Tuesday. The business’s 50-day moving average price is $2.23 and its 200-day moving average price is $2.27. Compugen has a 12 month low of $1.29 and a 12 month high of $3.23. The firm has a market capitalization of $227.87 million, a price-to-earnings ratio of 6.34 and a beta of 2.77.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Compugen had a net margin of 47.56% and a return on equity of 42.57%. The company had revenue of $2.60 million for the quarter, compared to analyst estimates of $1.28 million. During the same quarter in the previous year, the business earned ($0.08) earnings per share. On average, sell-side analysts predict that Compugen will post -0.27 earnings per share for the current fiscal year.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.